Pasar al contenido principal

NUEVAS ESTRATEGIAS CONTRA LA RESISTENCIA A LA TERAPIA EN CANCER DE MAMA

SAF2017-84934-R

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2017
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario ASOCIACION CENTRO DE INVESTIGACION COOP EN BIOCIENCIAS CIC BIOGUNE

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Tumor Suppressor ING5 Is a Dimeric, Bivalent Recognition Molecule of the Histone H3K4me3 Mark

  • Ormaza, Georgina
  • Rodríguez, Jhon A.
  • Ibáñez de Opakua, Alain
  • Merino, Nekane
  • Villate, Maider
  • Gorroño, Irantzu
  • Rábano, Miriam
  • Palmero, Ignacio
  • Vilaseca, Marta
  • Kypta, Robert M.
  • Vivanco, María d. M.
  • Rojas, Adriana L.
  • Blanco, Francisco J.
The INhibitor of Growth (ING) family of tumor suppressors regulates the transcriptional state of chromatin by recruiting remodeling complexes to sites with histone H3 trimethylated at lysine 4 (H3K4me3). This modification is recognized by the plant homeodomain (PHD) present at the C-terminus of the five ING proteins. ING5 facilitates histone H3 acetylation by the HBO1 complex, and also H4 acetylation by the MOZ/MORF complex. We show that ING5 forms homodimers through its N-terminal domain, which folds independently into an elongated coiled-coil structure. The central region of ING5, which contains the nuclear localization sequence, is flexible and disordered, but it binds dsDNA with micromolar affinity. NMR analysis of the full-length protein reveals that the two PHD fingers of the dimer are chemically equivalent and independent of the rest of the molecule, and they bind H3K4me3 in the same way as the isolated PHD. We have observed that ING5 can form heterodimers with the highly homologous ING4, and that two of three primary tumor-associated mutants in the N-terminal domain strongly destabilize the coiled-coil structure. They also affect cell proliferation and cell cycle phase distribution, suggesting a driver role in cancer progression., This work was supported by grant CTQ2017-83810-R (MINECO/FEDER/UE) to F.J.B., SAF2015-65690P to I.P., SAF2017-84092-R and SAF2014-51966-R to R.K., and SAF2017-84934-R to M.V. G.O. acknowledges a Formación de Personal Investigador Fellowship from MINECO (BES-2012-052851). We also thank MINECO for the Severo Ochoa Excellence Accreditation (SEV-2016-0644).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Nuclear receptors: Lipid and hormone sensors with essential roles in the control of cancer development

  • Font-Díaz, Joan
  • Jiménez-Panizo, Alba
  • Caelles, Carme
  • Vivanco, María d. M.
  • Pérez, Paloma
  • Aranda, Ana
  • Estébanez-Perpiñá, Eva
  • Castrillo, Antonio
  • Ricote, M. Mercedes
  • Valledor, Annabel F.
Versión de autor del artículo, 93 páginas, 3 figuras 1 tabla, Nuclear receptors (NRs) are a superfamily of ligand-activated transcription factors that act as biological sensors and use a combination of mechanisms to modulate positively and negatively gene expression in a spatial and temporal manner. The highly orchestrated biological actions of several NRs influence the proliferation, differentiation, and apoptosis of many different cell types. Synthetic ligands for several NRs have been the focus of extensive drug discovery efforts for cancer intervention. This review summarizes the roles in tumour growth and metastasis of several relevant NR family members, namely androgen receptor (AR), estrogen receptor (ER), glucocorticoid receptor (GR), thyroid hormone receptor (TR), retinoic acid receptors (RARs), retinoid X receptors (RXRs), peroxisome proliferator-activated receptors (PPARs), and liver X receptors (LXRs). These studies are key to develop improved therapeutic agents based on novel modes of action with reduced side effects and overcoming resistance., This work was supported by grants from the Spanish Ministry of Economy and Competitivity (MINECO) to AFV and CC (SAF2017-89510- R), to AA (SAF2017-83289-R), to MV (SAF2017-84934-R), to PP (SAF2017-88046-R), to EE (BFU2017-86906-R), and to the NuRCaMeIn network (SAF2017-90604REDT); grants from the Spanish Ministry of Science, Innovation and Universities (MCNU) and Fondo Europeo de Desarrollo Regional (FEDER) to MR (RTI2018-095928-B100) and AC (PID2019-104284RB-I00/AEI/10.13039/501100011033); a grant from Instituto de Salud Carlos III to AA (CIBERONC CB/16/00228); grants from the Autonomous Community of Madrid to AA (B2017/BMD-3724) and MR (MOIR-B2017/BMD-3684); grants from Fundació La Marato ´ de TV3 to CC (201605-30), AFV (201605-31) and MR (201605-32); a grant from the Government of the Autonomous Community of Basque Country, Department of Industry, Tourism and Trade to MV (Elkartek, KK-2018/ 00054); and a grant from La Caixa to EEP (CaixaImpulse-CI-0018). JFD received a fellowship from the Spanish Ministry of Science, Innovation and Universities (FPI, PRE2018-085579). The CNIC is supported by the MCNU and the Pro CNIC Foundation and is a Severo Ochoa Centre of Excellence (SEV-2015-0505). CIC bioGUNE is a Severo Ochoa Centre of Excellence (SEV-2016-0644), Peer reviewed